Clinical Trial Update: Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating memantine as an adjunctive treatment for schizophrenia has completed, with emphasis on safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: Forest Laboratories | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED